Seven Fleet Capital Management LP Sells 4,000 Shares of Protagonist Therapeutics, Inc. $PTGX

Seven Fleet Capital Management LP lowered its holdings in shares of Protagonist Therapeutics, Inc. (NASDAQ:PTGX) by 50.0% during the 1st quarter, according to the company in its most recent filing with the SEC. The fund owned 4,000 shares of the company’s stock after selling 4,000 shares during the period. Seven Fleet Capital Management LP’s holdings in Protagonist Therapeutics were worth $422,000 as of its most recent filing with the SEC.

A number of other large investors also recently added to or reduced their stakes in the business. Farther Finance Advisors LLC increased its stake in shares of Protagonist Therapeutics by 110.6% in the fourth quarter. Farther Finance Advisors LLC now owns 297 shares of the company’s stock worth $26,000 after buying an additional 156 shares during the period. Greenline Wealth Management LLC purchased a new stake in Protagonist Therapeutics during the 4th quarter valued at $27,000. EverSource Wealth Advisors LLC boosted its position in Protagonist Therapeutics by 63.0% during the 1st quarter. EverSource Wealth Advisors LLC now owns 911 shares of the company’s stock valued at $96,000 after buying an additional 352 shares during the period. Hantz Financial Services Inc. grew its holdings in Protagonist Therapeutics by 222.4% in the 4th quarter. Hantz Financial Services Inc. now owns 951 shares of the company’s stock worth $83,000 after acquiring an additional 656 shares during the last quarter. Finally, Canton Hathaway LLC bought a new stake in Protagonist Therapeutics in the 4th quarter worth $87,000. Hedge funds and other institutional investors own 98.63% of the company’s stock.

Insider Activity at Protagonist Therapeutics

In other news, Director Bryan Giraudo sold 36,000 shares of the business’s stock in a transaction on Thursday, May 7th. The stock was sold at an average price of $100.14, for a total value of $3,605,040.00. Following the completion of the transaction, the director owned 27,825 shares in the company, valued at $2,786,395.50. The trade was a 56.40% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, CEO Dinesh V. Ph D. Patel sold 75,000 shares of the company’s stock in a transaction on Tuesday, May 12th. The shares were sold at an average price of $100.12, for a total value of $7,509,000.00. Following the transaction, the chief executive officer directly owned 523,478 shares in the company, valued at approximately $52,410,617.36. The trade was a 12.53% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last three months, insiders have sold 161,130 shares of company stock valued at $16,355,220. 5.19% of the stock is owned by corporate insiders.

Protagonist Therapeutics Stock Performance

Shares of Protagonist Therapeutics stock opened at $136.64 on Friday. The company has a 50-day simple moving average of $120.38 and a two-hundred day simple moving average of $103.23. The stock has a market capitalization of $8.79 billion, a PE ratio of -75.49 and a beta of 1.79. Protagonist Therapeutics, Inc. has a 52-week low of $50.49 and a 52-week high of $143.29.

Protagonist Therapeutics (NASDAQ:PTGX) last posted its quarterly earnings results on Tuesday, May 5th. The company reported $0.05 EPS for the quarter, beating analysts’ consensus estimates of ($0.50) by $0.55. The firm had revenue of $56.37 million for the quarter, compared to analysts’ expectations of $11.70 million. Protagonist Therapeutics had a negative net margin of 154.88% and a negative return on equity of 17.76%. As a group, equities research analysts forecast that Protagonist Therapeutics, Inc. will post 3.69 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of research analysts recently issued reports on the company. Truist Financial boosted their price target on Protagonist Therapeutics from $121.00 to $145.00 and gave the company a “buy” rating in a report on Tuesday, July 7th. The Goldman Sachs Group reiterated a “neutral” rating and issued a $110.00 price objective on shares of Protagonist Therapeutics in a report on Wednesday, May 6th. Wolfe Research assumed coverage on Protagonist Therapeutics in a research report on Thursday, May 21st. They issued an “outperform” rating and a $135.00 price objective on the stock. Citizens Jmp boosted their target price on Protagonist Therapeutics from $120.00 to $137.00 and gave the company a “market outperform” rating in a research note on Wednesday, May 6th. Finally, Wall Street Zen upgraded Protagonist Therapeutics from a “buy” rating to a “strong-buy” rating in a report on Saturday, July 25th. Two investment analysts have rated the stock with a Strong Buy rating, thirteen have given a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, Protagonist Therapeutics currently has a consensus rating of “Moderate Buy” and a consensus price target of $123.00.

About Protagonist Therapeutics

Protagonist Therapeutics, Inc (NASDAQ: PTGX) is a clinical-stage biopharmaceutical company focused on the development of novel, orally administered peptide-based therapies for immune-mediated and other serious diseases. The company leverages its proprietary Peptide 2.0 platform to design peptides that target G protein–coupled receptors and cytokine receptors, with the goal of combining the potency of biologics with the convenience of oral administration. Protagonist’s approach aims to address unmet medical needs in areas where injectable therapies have been the standard of care.

Among its lead programs is PTG-100, an oral α4β7 integrin antagonist intended to block leukocyte migration to the gut in ulcerative colitis and Crohn’s disease.